Exploring combined therapeutic strategies: S-adenosylmethionine (SAM) and conventional medications in polycystic ovary syndrome (PCOS) management
Abstract
Polycystic Ovary Syndrome (PCOS) remains a prevalent endocrine disorder among women of reproductive age, with treatments often facing significant limitations. This research article delves into an innovative therapeutic strategy that bridges the potential epigenetic capabilities of S-adenosylmethionine (SAM) with the established benefits of traditional PCOS medications, notably metformin and contraceptive pills. Drawing inspiration from contemporary literature, the manuscript highlights the limited role of SAM in DNA methylation processes and the unclear long-term effects of Sam in attenuating PCOS-related traits in specific animal models. The paper meticulously outlines an experimental design, encapsulating aspects such as precise drug formulation, systematic administration regimens, and methodical data collection and analysis techniques. Such a holistic approach facilitates a robust evaluation of the synergetic effects of combining SAM with established drugs. In spotlighting this combined therapeutic method, the article aspires to offer fresh perspectives in the realm of PCOS management, ultimately emphasizing the pivotal importance of subsequent clinical trials and more extensive studies in solidifying these preliminary findings.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.